We are live on ! Find out more
PMVP icon

PMV Pharmaceuticals
PMVP

51 hedge funds and large institutions have $1.09B invested in PMV Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 51 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

72.59% more ownership

Funds ownership: 0% → 72.59% (+73%)

Holders
51
Holders Change
+51
Holders Change %
–
% of All Funds
1.03%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.06%
New
51
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$270M
2
IVM
InterWest Venture Management
California
+$238M
3
Viking Global Investors
Viking Global Investors
Connecticut
+$97.2M
4
BC
Boxer Capital
California
+$83.5M
5
ACA
Avoro Capital Advisors
New York
+$68.1M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$260M +$270M +7,330,423 New
IVM
2
InterWest Venture Management
California
$230M +$238M +6,469,911 New
Viking Global Investors
3
Viking Global Investors
Connecticut
$93.8M +$97.2M +2,641,840 New
BC
4
Boxer Capital
California
$80.5M +$83.5M +2,268,236 New
RCM
5
RA Capital Management
Massachusetts
$60.7M +$62.9M +1,710,265 New
ACA
6
Avoro Capital Advisors
New York
$57.6M +$68.1M +1,850,000 New
Wellington Management Group
7
Wellington Management Group
Massachusetts
$57.1M +$60.6M +1,645,822 New
PA
8
Perceptive Advisors
New York
$21.5M +$22.3M +605,556 New
Victory Capital Management
9
Victory Capital Management
Texas
$19.8M +$20.5M +557,843 New
BlackRock
10
BlackRock
New York
$19.2M +$19.9M +542,038 New
RI
11
RTW Investments
New York
$17.8M +$18.4M +500,000 New
Alkeon Capital Management
12
Alkeon Capital Management
New York
$16.9M +$17.5M +475,000 New
Fidelity Investments
13
Fidelity Investments
Massachusetts
$14.6M +$15.1M +411,200 New
ACH
14
ArrowMark Colorado Holdings
Colorado
$14.2M +$14.7M +400,000 New
Invesco
15
Invesco
Georgia
$14.2M +$14.7M +400,000 New
Janus Henderson Group
16
Janus Henderson Group
United Kingdom
$12.8M +$13.3M +361,724 New
UBS AM
17
UBS AM
Illinois
$12.4M +$12.9M +350,000 New
Federated Hermes
18
Federated Hermes
Pennsylvania
$8.88M +$9.2M +250,000 New
DCM
19
Driehaus Capital Management
Illinois
$8.43M +$8.74M +237,563 New
WP
20
Woodline Partners
California
$7.36M +$7.63M +207,421 New
Principal Financial Group
21
Principal Financial Group
Iowa
$7.13M +$7.39M +200,800 New
AG
22
Artal Group
Luxembourg
$7.1M +$7.36M +200,000 New
Franklin Resources
23
Franklin Resources
California
$7.1M +$7.36M +200,000 New
Goldman Sachs
24
Goldman Sachs
New York
$5.96M +$6.17M +167,751 New
APM
25
Avidity Partners Management
Texas
$5.33M +$5.52M +150,000 New
1
2 3

PMVP Hedge Fund Activity: Q3 2020 in Review

51 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in PMV Pharmaceuticals (PMVP) for Q3 2020, worth a combined $1.09B.

Buyers outnumbered sellers: 51 funds opened new PMVP positions and 0 closed out — a net gain of 51 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was OrbiMed, opening a new position worth an estimated $270M.

  • 51 institutional investors held PMV Pharmaceuticals (PMVP) as of Q3 2020, up from 0 in Q2 2020.
  • Funds reported $1.09B of PMV Pharmaceuticals stock for Q3 2020.
  • 51 funds opened new PMV Pharmaceuticals positions in Q3 2020 and 0 closed out, a net change of +51 holders.
  • The largest PMV Pharmaceuticals buyer in Q3 2020 was OrbiMed, an estimated $270M added.

Based on aggregated 13F filings for Q3 2020.